Drugs / RGB-5088
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06731218 | Feb 2025 → Dec 2027 expected | type 1 diabetes mellitus | Hangzhou Reprogenix Bioscience, Inc | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGB-5088 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06731218 ↗ |
| Modality | Cell therapy | “RGB-5088 islet cell transplantation” NCT06731218 ↗ |
| Route | Other | “Transplantation under the anterior rectus sheath” NCT06731218 ↗ |